



Clinical trial results:

An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial-Onset Seizures or Primary Generalized Tonic-Clonic Seizures

Summary

EudraCT number	2014-002167-16
Trial protocol	HU LV ES PL BE IT Outside EU/EEA
Global end of trial date	06 December 2021

Results information

Result version number	v1 (current)
This version publication date	17 June 2022
First version publication date	17 June 2022

Trial information

Trial identification

Sponsor protocol code	E2007-G000-311
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02849626
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Eisai Ltd
Sponsor organisation address	European Knowledge Centre Mosquito Way, Hatfield Hertfordshire, United Kingdom, AL10 9SN
Public contact	EMA Medical Information, Eisai Europe Ltd., +44 (0)208 600 1400, EUMedInfo@eisai.net
Scientific contact	EMA Medical Information, Eisai Europe Ltd., +44 (0)208 600 1400, EUMedInfo@eisai.net

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000467-PIP01-08
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 December 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 December 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than [$<$] 12 years) with inadequately controlled partial onset seizures (POS) or primary generalized tonic clonic (PGTC) seizures.

Protection of trial subjects:

This study was conducted in accordance with standard operating procedures (SOPs) of the sponsor (or designee), which are designed to ensure adherence to Good Clinical Practice (GCP) guidelines as required by the following: - Principles of the World Medical Association Declaration of Helsinki (World Medical Association, 2008) - International Council on Harmonisation (ICH) E6 Guideline for GCP (CPMP/ICH/135/95) of the European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use - Title 21 of the United States (US) Code of Federal Regulations (US 21 CFR) regarding clinical studies, including Part 50 and Part 56 concerning informed subject consent and Institutional Review Board (IRB) regulations and applicable sections of US 21 CFR Part 312 - European Good Clinical Practice Directive 2005/28/EC and Clinical Trial Directive 2001/20/EC for studies conducted within any European Union (EU) country. All suspected unexpected serious adverse reactions were reported, as required, to the Competent Authorities of all involved EU member states. - Article 14, Paragraph 3, and Article 80-2 of the Pharmaceutical Affairs Law (Law No. 145, 1960) for studies conducted in Japan, in addition to Japan's GCP Subject Information and Informed Consent.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 November 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	1 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 5
Country: Number of subjects enrolled	France: 10
Country: Number of subjects enrolled	Hungary: 26
Country: Number of subjects enrolled	Japan: 65
Country: Number of subjects enrolled	Latvia: 6
Country: Number of subjects enrolled	Poland: 16

Country: Number of subjects enrolled	Korea, Republic of: 1
Country: Number of subjects enrolled	Spain: 14
Country: Number of subjects enrolled	United States: 37
Worldwide total number of subjects	180
EEA total number of subjects	77

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	180
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects took part at 58 sites in the United States, European Union, Asia Pacific. 208 subjects were screened/enrolled. Of which 28 screen failures and 180 received treatment in Core Phase. Of 146 who completed Core Phase, 136 entered Extension Phase A. Of 122 who completed Extension Phase A, 42 entered Extension Phase B and 41 received treatment.

Pre-assignment

Screening details:

This study included a Core Phase and two Extension Phases (Extension Phase A and Extension Phase B).

Period 1

Period 1 title	Core Phase (up to 23 weeks)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Perampanel 0.5 mg/mL: POS

Arm description:

Core Phase: Subjects with partial onset-seizures (POS) received perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension titrated beyond 8 milligram per day (mg/day) up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any enzyme-inducing antiepileptic drug [EIAED]), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Arm type	Experimental
Investigational medicinal product name	Perampanel
Investigational medicinal product code	
Other name	E2007
Pharmaceutical forms	Oral drops, suspension
Routes of administration	Oral use

Dosage and administration details:

Perampanel 0.5 mg/mL oral suspension

Arm title	Perampanel 0.5 mg/mL: PGTC Seizures
------------------	-------------------------------------

Arm description:

Core Phase: Subjects with primary generalized tonic clonic (PGTC) seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any other EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel oral suspension once daily at the optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed the Core Phase, entered the Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Perampanel
Investigational medicinal product code	
Other name	E2007
Pharmaceutical forms	Oral drops, suspension
Routes of administration	Oral use

Dosage and administration details:

Perampanel 0.5 mg/mL oral suspension

Number of subjects in period 1	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures
Started	149	31
Completed	122	24
Not completed	27	7
Inadequate Therapeutic Effect	6	2
Consent withdrawn by subject	7	2
Non-specified	3	-
Adverse event, non-fatal	11	3

Period 2

Period 2 title	Extension Phase A (up to 29 weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Perampanel 0.5 mg/mL: POS

Arm description:

Core Phase: Subjects with POS received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any [EIAED]), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Arm type	Experimental
Investigational medicinal product name	Perampanel
Investigational medicinal product code	
Other name	E2007
Pharmaceutical forms	Oral drops, suspension
Routes of administration	Oral use

Dosage and administration details:

Perampanel 0.5 mg/mL oral suspension

Arm title	Perampanel 0.5 mg/mL: PGTC Seizures
Arm description:	
Core Phase: Subjects with PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any other EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel oral suspension once daily at the optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed the Core Phase, entered the Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.	
Arm type	Experimental
Investigational medicinal product name	Perampanel
Investigational medicinal product code	
Other name	E2007
Pharmaceutical forms	Oral drops, suspension
Routes of administration	Oral use
Dosage and administration details:	
Perampanel 0.5 mg/mL oral suspension	

Number of subjects in period 2^[1]	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures
Started	116	20
Completed	105	17
Not completed	11	3
Inadequate Therapeutic Effect	3	1
Consent withdrawn by subject	4	-
Non-specified	1	-
Adverse event, non-fatal	3	2

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only eligible participants who completed Core Phase entered into Extension Phase A.

Period 3

Period 3 title	Extension Phase B (up to 89 weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Extension B: Perampanel 0.5 mg/mL: POS

Arm description:

Subjects who completed Core Phase and Extension Phase A entered Extension Phase B, and continued with their optimal perampanel dose from Core Phase until a subject reached 12 years of age, switched to the commercial perampanel product, or discontinued for safety or administrative reasons.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Perampanel
Investigational medicinal product code	
Other name	E2007
Pharmaceutical forms	Oral drops, suspension
Routes of administration	Oral use
Dosage and administration details: Perampanel 0.5 mg/mL oral suspension	
Arm title	Extension B: Perampanel 0.5 mg/mL: PGTC Seizures

Arm description:

Subjects who completed Core Phase and Extension Phase A entered Extension Phase B, and continued with their optimal perampanel dose from Core Phase until a subject reached 12 years of age, switched to the commercial perampanel product, or discontinued for safety or administrative reasons.

Arm type	Experimental
Investigational medicinal product name	Perampanel
Investigational medicinal product code	
Other name	E2007
Pharmaceutical forms	Oral drops, suspension
Routes of administration	Oral use

Dosage and administration details:

Perampanel 0.5 mg/mL oral suspension

Number of subjects in period 3 ^[2]	Extension B: Perampanel 0.5 mg/mL: POS	Extension B: Perampanel 0.5 mg/mL: PGTC Seizures
Started	41	1
Completed	36	1
Not completed	5	0
Inadequate Therapeutic Effect	3	-
Unspecified	1	-
Subject choice	1	-

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only eligible participants who completed Core Phase and Extension A entered into Extension Phase B.

Baseline characteristics

Reporting groups

Reporting group title	Perampanel 0.5 mg/mL: POS
-----------------------	---------------------------

Reporting group description:

Core Phase: Subjects with partial onset-seizures (POS) received perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension titrated beyond 8 milligram per day (mg/day) up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any enzyme-inducing antiepileptic drug [EIAED]), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Reporting group title	Perampanel 0.5 mg/mL: PGTC Seizures
-----------------------	-------------------------------------

Reporting group description:

Core Phase: Subjects with primary generalized tonic clonic (PGTC) seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any other EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel oral suspension once daily at the optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed the Core Phase, entered the Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Reporting group values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures	Total
Number of subjects	149	31	180
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	149	31	180
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	8.1	8.5	-
standard deviation	± 2.10	± 2.03	
Sex: Female, Male			
Units: subjects			
Female	77	11	88
Male	72	20	92

Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	3	7	10
Not Hispanic or Latino	141	19	160
Unknown or Not Reported	5	5	10
Race/Ethnicity, Customized			
Units: Subjects			
White	70	23	93
Black or African American	2	1	3
Japanese	65	0	65
Other Asian	5	1	6
American Indian or Alaska Native	1	0	1
Other	2	1	3
Missing	4	5	9

End points

End points reporting groups

Reporting group title	Perampanel 0.5 mg/mL: POS
-----------------------	---------------------------

Reporting group description:

Core Phase: Subjects with partial onset-seizures (POS) received perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension titrated beyond 8 milligram per day (mg/day) up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any enzyme-inducing antiepileptic drug [EIAED]), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Reporting group title	Perampanel 0.5 mg/mL: PGTC Seizures
-----------------------	-------------------------------------

Reporting group description:

Core Phase: Subjects with primary generalized tonic clonic (PGTC) seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any other EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel oral suspension once daily at the optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed the Core Phase, entered the Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Reporting group title	Perampanel 0.5 mg/mL: POS
-----------------------	---------------------------

Reporting group description:

Core Phase: Subjects with POS received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any [EIAED]), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Reporting group title	Perampanel 0.5 mg/mL: PGTC Seizures
-----------------------	-------------------------------------

Reporting group description:

Core Phase: Subjects with PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any other EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel oral suspension once daily at the optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed the Core Phase, entered the Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Reporting group title	Extension B: Perampanel 0.5 mg/mL: POS
-----------------------	--

Reporting group description:

Subjects who completed Core Phase and Extension Phase A entered Extension Phase B, and continued with their optimal perampanel dose from Core Phase until a subject reached 12 years of age, switched to the commercial perampanel product, or discontinued for safety or administrative reasons.

Reporting group title	Extension B: Perampanel 0.5 mg/mL: PGTC Seizures
-----------------------	--

Reporting group description:

Subjects who completed Core Phase and Extension Phase A entered Extension Phase B, and continued with their optimal perampanel dose from Core Phase until a subject reached 12 years of age, switched to the commercial perampanel product, or discontinued for safety or administrative reasons.

Subject analysis set title	Perampanel 0.5 mg/mL: All Subjects
Subject analysis set type	Safety analysis

Subject analysis set description:

Core Phase: Subjects with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Subject analysis set title	Perampanel 0.5 mg/mL: All Subjects
Subject analysis set type	Safety analysis

Subject analysis set description:

Core Phase: Subjects with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Subject analysis set title	Perampanel 0.5 mg/mL: All Subjects
Subject analysis set type	Safety analysis

Subject analysis set description:

Core Phase: Subjects with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Subject analysis set title	Perampanel: POS
Subject analysis set type	Safety analysis

Subject analysis set description:

All subjects with POS who received perampanel 0.5 mg/mL oral suspension (for subjects with age less than [$<$] 12 years) or tablets (for subjects with age \geq 12 years) titrated to a dose of up to 8 mg/day for up to 23 weeks in studies E2007-G000-304 (NCT00699972), E2007-G000-305 (NCT00699582), E2007-G000-306 (NCT00700310), E2007-J000-335 (NCT01618695) and this current study (E2007-G000-311).

Subject analysis set title	Perampanel: PGTC Seizures
Subject analysis set type	Safety analysis

Subject analysis set description:

All subjects with PGTC seizures who received perampanel 0.5 mg/mL oral suspension (for subjects with age $<$ 12 years) or tablets (for subjects with age \geq 12 years) titrated to a dose of up to 8 mg/day for up to 23 weeks in studies E2007-G000-232 (NCT01527006) and E2007-G000-332 (NCT01393743) and this current study (E2007-G000-311).

Subject analysis set title	Perampanel: Subjects aged ($<$ 12 years)
Subject analysis set type	Safety analysis

Subject analysis set description:

All non-Asian subjects with POS, received perampanel oral suspension (subjects with age $<$ 12 years) titrated to a dose of up to 8 mg/day or up to 12 mg/day for up to 23 weeks in this current study E2007-G000-311.

Subject analysis set title	Perampanel: Subjects aged (\geq 12 years)
Subject analysis set type	Safety analysis

Subject analysis set description:

All non-Asian subjects with POS, received perampanel tablets (subjects with age \geq 12 years) titrated to

a dose of up to 8 mg/day or up to 12 mg/day for up to 23 weeks in studies E2007-G000-304 (NCT00699972), E2007-G000-305 (NCT00699582), E2007-G000-306 (NCT00700310), E2007-J000-335 (NCT01618695).

Subject analysis set title	Perampanel: Without Topiramate
Subject analysis set type	Safety analysis
Subject analysis set description:	
All subjects with PGTC seizures received perampanel as oral suspension (aged <12 years) or as oral tablets (aged ≥12 years) titrated to a dose of up to 8 mg/day or up to 12 mg/day without topiramate for up to 23 weeks in studies E2007-G000-232 (NCT01527006) and E2007-G000-332 (NCT01393743) and this current study (E2007-G000-311).	
Subject analysis set title	Perampanel: With Topiramate
Subject analysis set type	Safety analysis
Subject analysis set description:	
All subjects with PGTC seizures received perampanel as oral suspension (aged <12 years) or as oral tablets (aged ≥12 years) titrated to a dose of up to 8 mg/day or up to 12 mg/day along with topiramate for up to 23 weeks in studies E2007-G000-232 (NCT01527006) and E2007-G000-332 (NCT01393743) and this current study (E2007-G000-311).	
Subject analysis set title	Perampanel: POS
Subject analysis set type	Safety analysis
Subject analysis set description:	
All subjects with POS who received perampanel 0.5 mg/mL oral suspension (for subjects with age <12 years) or tablets (for subjects with age ≥12 years) titrated to a dose of up to 8 mg/day for up to 23 weeks in studies E2007-G000-304 (NCT00699972), E2007-G000-305 (NCT00699582), E2007-G000-306 (NCT00700310), E2007-J000-335 (NCT01618695) and this current study (E2007-G000-311).	
Subject analysis set title	Perampanel 0.5 mg/mL: All Subjects
Subject analysis set type	Safety analysis
Subject analysis set description:	
Core Phase: Subjects with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.	
Subject analysis set title	Perampanel 0.5 mg/mL: All Subjects
Subject analysis set type	Safety analysis
Subject analysis set description:	
Core Phase: Subjects with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.	
Subject analysis set title	Perampanel 0.5 mg/mL: All Subjects
Subject analysis set type	Safety analysis
Subject analysis set description:	
Core Phase: Subjects with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.	
Subject analysis set title	Perampanel 0.5 mg/mL: All Subjects

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Core Phase: Subjects with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Subject analysis set title	Perampanel 0.5 mg/mL: All Subjects
----------------------------	------------------------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Core Phase: Subjects with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Subject analysis set title	Perampanel 0.5 mg/mL: 4 to <7 Years
----------------------------	-------------------------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Core Phase: Subjects of age 4 to <7 years with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Subject analysis set title	Perampanel 0.5 mg/mL: 7 to <12 Years
----------------------------	--------------------------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Core Phase: Subjects of age 7 to <12 years with POS or PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any other EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel oral suspension once daily at the optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed the Core Phase, entered the Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Primary: Percentage of Subjects With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Subjects - Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Subjects - Core Phase and Extension Phase A of This Study ^[1]
-----------------	--

End point description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to 4 weeks (follow up in Extension Phase A) after last dose of study drug in Extension Phase

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for this endpoint.

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	180			
Units: percentage of subjects				
number (not applicable)				
Treatment Emergent AEs	90.0			
Treatment Emergent SAEs	20.0			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects With Treatment Emergent Markedly Abnormal Laboratory Values for Total Group of Subjects - Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects With Treatment Emergent Markedly Abnormal Laboratory Values for Total Group of Subjects - Core Phase and Extension Phase A of This Study ^[2]
-----------------	--

End point description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to 52 weeks

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for this endpoint.

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	180			
Units: percentage of subjects				
number (not applicable)				
Potassium: Markedly Abnormal High (n=177)	0.6			
Sodium: Markedly Abnormal Low (n=177)	1.1			
Alanine Aminotransferase: Abnormal High (n=177)	1.1			
Calcium: Abnormal Low (n=177)	0.6			
Gamma Glutamyl Transferase: Abnormal High (n=177)	2.8			
Neutrophils: Abnormal Low (n=176)	9.1			

Hemoglobin: Abnormal Low (n=176)	1.7			
Leukocytes: Abnormal Low (n=176)	0.6			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects With Abnormal Vital Sign Values for Total Group of Subjects- Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects With Abnormal Vital Sign Values for Total Group of Subjects- Core Phase and Extension Phase A of This Study ^[3]
-----------------	---

End point description:

Pre-defined criteria of vital signs abnormalities: maximum (max.) increase or decrease from baseline in sitting/supine systolic blood pressure (SBP) of greater than or equal to (\geq) 20 or 40 millimeter of mercury (mmHg); maximum increase or decrease from baseline in sitting/supine diastolic blood pressure (DBP) \geq 10 or 20 mmHg; increase or decrease from baseline in pulse rate (number of heart beats per minute [bpm]) of \geq 15 or 30 bpm. Data for this outcome measure has been assessed and reported till Week 52. SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment. Here "number of subjects analyzed" signifies subjects who were evaluable for this outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to 52 weeks

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for this endpoint.

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	179			
Units: percentage of subjects				
number (not applicable)				
Systolic Blood Pressure: Increment \geq 20 mmHg	24.6			
Systolic Blood Pressure: Increment \geq 40 mmHg	2.2			
Systolic Blood Pressure: Decrement \geq 20 mmHg	20.1			
Systolic Blood Pressure: Decrement \geq 40 mmHg	0.6			
Diastolic Blood Pressure: Increment \geq 10 mmHg	48.0			
Diastolic Blood Pressure: Increment \geq 20 mmHg	26.8			
Diastolic Blood Pressure: Decrement \geq 10 mmHg	38.0			
Diastolic Blood Pressure: Decrement \geq 20 mmHg	16.8			
Pulse: Increment \geq 15 bpm	35.8			
Pulse: Increment \geq 30 bpm	11.7			

Pulse: Decrement ≥ 15 bpm	39.7			
Pulse: Decrement ≥ 30 bpm	13.4			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects With Markedly Abnormal Electrocardiogram (ECG) Parameters for Total Group of Subjects - Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects With Markedly Abnormal Electrocardiogram (ECG) Parameters for Total Group of Subjects - Core Phase and Extension Phase A of This Study ^[4]
-----------------	--

End point description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment. Here "number of subjects analyzed" signifies subjects who were evaluable for this outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to 52 weeks

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for this endpoint.

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	174			
Units: percentage of subjects				
number (not applicable)				
QTc Bazett: Increase of >30 millisecond (msec)	8.0			
QTc Bazett: Increase of >60 msec	0			
QTc Bazett: >450 msec	4.0			
QTc Bazett: >480 msec	0			
QTc Bazett: >500 msec	0			
QTc Fridericia: Increase of >30 msec	5.2			
QTc Fridericia: Increase of >60 msec	0			
QTc Fridericia: >450 msec	0			
QTc Fridericia: >480 msec	0			
QTc Fridericia: >500 msec	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Model Predicted Percent Change in Average Seizure Frequency Over 28 Days During Maintenance Period in Core Phase of This Study From Baseline- Assessed as Relationship With Average Steady State Plasma Concentration (Cav, ss) of Perampanel (518 ng/mL)

End point title	Model Predicted Percent Change in Average Seizure Frequency Over 28 Days During Maintenance Period in Core Phase of This Study From Baseline- Assessed as Relationship With Average Steady State Plasma Concentration (Cav, ss) of Perampanel (518 ng/mL)
-----------------	---

End point description:

Seizure frequency was derived from information recorded in subject diary. Seizure frequency per 28 days calculated as number of seizures divided by number of days in the interval and multiplied by 28. Due to sparse pharmacokinetic (PK) sampling, data of OM was analyzed by pooling data from other Phase II/III studies of perampanel along with data of current study, subjects with POS or PGTC. Only data for subjects taking perampanel 8 mg/day (Cav, ss of 518 ng/mL) were reported. Subjects taking perampanel 12 mg/day in the studies from which data were pooled, were not included in analysis. ng/mL refers to nanogram per milliliter. Data for this OM was calculated through model prediction. All subjects who received perampanel who have seizure frequency, cognition, or AE data with documented dosing history. Population for this OM included subjects from other studies as well subjects from current study. Here "number of subject analyzed" signifies subjects evaluable for this measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 23

End point values	Perampanel: POS	Perampanel: PGTC Seizures		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	1371	92		
Units: percent change				
number (not applicable)	-43.1	-63.6		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Responder Probability For Non-Asian Subjects With POS During Core Phase of This Study: Assessment Based on Relationship With Average Steady State Plasma Concentration (Cav, ss) of Perampanel

End point title	Overall Responder Probability For Non-Asian Subjects With POS During Core Phase of This Study: Assessment Based on Relationship With Average Steady State Plasma Concentration (Cav, ss) of Perampanel
-----------------	--

End point description:

For this OM, responders were those who experienced a 50 percent (%) or greater reduction in seizure frequency per 28 days from baseline. Due to the sparse PK sampling in this study, the data of this OM were pooled with data from other Phase III studies of perampanel conducted in subjects with POS. "AEDs not affecting PK" refers to AEDs not affecting PK of perampanel. Data for this OM has been reported for only non-Asian subjects with POS per age groups. Responder probability has been reported for Cav,ss of perampanel when given along with different antiepileptic drugs (AEDs). All subjects who received perampanel who have seizure frequency, cognition, or AE data with documented dosing history. Population for this OM included subjects from other studies as well subjects from this current study. Here "number of subjects analyzed" signifies subjects who were evaluable for this measure.

End point type	Secondary
----------------	-----------

End point timeframe:
Baseline up to 23 weeks

End point values	Perampanel: Subjects aged (<12 years)	Perampanel: Subjects aged (≥12 years)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	123	1420		
Units: Responder probability				
number (not applicable)				
8 mg/day+ AEDs not affecting PK:Cav ss 518 ng/mL	0.605	0.466		
12 mg/day+ AEDs not affecting PK:Cav ss 778 ng/mL	0.669	0.535		
8 mg/day+ Oxcarbazepine/Phenytoin:Cav ss 258	0.520	0.382		
12 mg/day+ Oxcarbazepine/Phenytoin:Cav	0.565	0.426		
8 mg/day+ Carbamazepine:Cav ss 175 ng/mL	0.485	0.350		
12 mg/day+ Carbamazepine:Cav ss 263 ng/mL	0.522	0.384		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Responder Probability For Subjects With PGTC Seizures During Core Phase of This Study: Assessment Based on Relationship With Average Steady State Plasma Concentration (Cav, ss) of Perampanel

End point title	Overall Responder Probability For Subjects With PGTC Seizures During Core Phase of This Study: Assessment Based on Relationship With Average Steady State Plasma Concentration (Cav, ss) of Perampanel
-----------------	--

End point description:

For this OM, responders were those who experienced a 50% or greater reduction in seizure frequency per 28 days from baseline. Due to the sparse PK sampling in this study, the data of this OM were analyzed by pooling the data from other Phase II and III studies of perampanel along with data of this current study, including subjects with PGTC seizures. In this outcome measure, responder probability at different concentration values of perampanel when given with or without topiramate (an antiepileptic) has been reported to compare the effect of topiramate on responder probability. All subjects who received perampanel who have seizure frequency, cognition, or AE data with documented dosing history. Population for this measure included subjects from other studies as well subjects from this current study. Here "number of subjects analyzed" signifies subjects who were evaluable for this measure.

End point type	Secondary
End point timeframe:	
Baseline up to 23 weeks	

End point values	Perampanel: Without Topiramate	Perampanel: With Topiramate		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	138	31		
Units: Responder probability				
number (not applicable)				
0 ng/mL	0.46	0.26		
100 ng/mL	0.71	0.50		
200 ng/mL	0.74	0.54		
300 ng/mL	0.76	0.57		
400 ng/mL	0.77	0.58		
500 ng/mL	0.78	0.59		
600 ng/mL	0.79	0.60		
700 ng/mL	0.80	0.61		
800 ng/mL	0.80	0.62		
900 ng/mL	0.80	0.63		
1000 ng/mL	0.81	0.63		
1200 ng/mL	0.82	0.64		
1400 ng/mL	0.82	0.65		
1600 ng/mL	0.82	0.66		
1800 ng/mL	0.83	0.66		
2000 ng/mL	0.83	0.67		
2200 ng/mL	0.84	0.67		
2400 ng/mL	0.84	0.68		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Seizure Free Observations During Core Phase of This Study: Assessment Based on Relationship With Average Steady State Plasma Concentration (Cav, ss) of Perampanel

End point title	Number of Seizure Free Observations During Core Phase of This Study: Assessment Based on Relationship With Average Steady State Plasma Concentration (Cav, ss) of Perampanel
-----------------	--

End point description:

Due to the sparse PK sampling in this study, the data of this OM were analyzed by pooling data from other Phase II and III studies of perampanel along with this current study, including subjects with POS or PGTC. Data for this OM have been reported in relationship with different ranges of Cav, ss of Perampanel as "number of observations" those were seizure free for up to 3 visits. The reason for using number of observations for analysis of this OM was because data were available as up to 3 visits per subjects and not necessarily that the subject was seizure-free on all three visits. All subjects who received perampanel who have seizure frequency, cognition, or AE data with documented dosing history. Population for this measure included subjects from other studies as well subjects from this current study. Here "number of subjects analyzed" signifies subjects who were evaluable for this measure and SFO denotes Seizure free observations.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 23

End point values	Perampanel: POS	Perampanel: PGTC Seizures		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	1371	92		
Units: Seizure free observations				
>0 - <500 ng/mL(3189,127:POS/PGTC SFO)	275	57		
500 - <1000 ng/mL(583,104:POS/PGTC SFO)	103	67		
1000 - <1500 ng/mL(159,15:POS/PGTC SFO)	33	11		
1500 - 2000 ng/mL(33,6:POS/PGTC SFO)	7	4		
>2000 ng/mL(10,3:POS/PGTC SFO)	0	3		

Statistical analyses

No statistical analyses for this end point

Secondary: Model Predicted Change From Baseline in Total Aldenkamp-Baker Neuropsychological Assessment Schedule (ABNAS) Score During Core Phase of this Study: Assessment Based on Relationship With Plasma Levels of Perampanel

End point title	Model Predicted Change From Baseline in Total Aldenkamp-Baker Neuropsychological Assessment Schedule (ABNAS) Score During Core Phase of this Study: Assessment Based on Relationship With Plasma Levels of Perampanel
-----------------	---

End point description:

The ABNAS assessment measured 5 aspects of cognitive function such as fatigue, memory, concentration, motor speed, and reading. The assessment was a measure of subject-perceived cognitive effects of AEDs. This instrument was aimed at assessing subject perceived drug-related cognitive impairment. Total score ranged from 0-72. Higher scores indicate a worsening of these cognitive functions. Analysis for this OM was planned to be performed via Pharmacokinetic/Pharmacodynamic (PK/PD) modelling only if a graphical relationship between perampanel exposure and change from baseline in ABNAS could be discerned. All subjects who received perampanel who have seizure frequency, cognition, or AE data with documented dosing history. Here "number of subjects analyzed" signifies subjects who were evaluable for this outcome measure and 99999 signifies no discernible graphical relationship between plasma level of perampanel and change from baseline.

End point type	Secondary
End point timeframe:	
Baseline up to Week 23	

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	148			
Units: score on a scale				
arithmetic mean (standard deviation)	99999 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Model Predicted Change From Baseline in Total Child Behavior Check List (CBCL) Score (Subjects Aged 4 to 5 Years) During Core Phase of This Study: Assessment Based on Relationship With Plasma Levels of Perampanel

End point title	Model Predicted Change From Baseline in Total Child Behavior Check List (CBCL) Score (Subjects Aged 4 to 5 Years) During Core Phase of This Study: Assessment Based on Relationship With Plasma Levels of Perampanel
-----------------	--

End point description:

CBCL for subjects with age 4-5 years is questionnaire to assess behavioral;emotional problems in children as reported by primary caregiver for following domains activities: emotionally reactive, anxious/depressed, withdrawn, somatic complaints, internalizing, attention problems, aggressive behavior, externalizing, sleep problems. CBCL total score ranged from 0 to 200,calculated by adding individual score of each domain. Higher scores greater problems in child behavior. Analysis for this OM was planned to be performed via PK/PD modelling only if graphical relationship between perampanel exposure; change from baseline in CBCL score (subjects aged 4 to 5 years) could be discerned. All subjects who received perampanel who have seizure frequency, cognition, or AE data with documented dosing history. Here "number of subjects analyzed": subjects who were evaluable for this OM and 99999 signifies no discernible graphical relationship between plasma level of perampanel; change from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 23

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	19			
Units: score on a scale				
arithmetic mean (standard deviation)	99999 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Model Predicted Change From Baseline in Total Child Behavior Check List (CBCL) Score (Subjects Aged Greater Than [>] 5 to <12 Years) During Core Phase of This Study: Assessment Based on Relationship With Plasma Levels of Perampanel

End point title	Model Predicted Change From Baseline in Total Child Behavior Check List (CBCL) Score (Subjects Aged Greater Than [>] 5 to <12 Years) During Core Phase of This Study: Assessment
-----------------	--

End point description:

CBCL for subjects >5 -<12 years questionnaire to assess behavioral;emotional problems in children reported by primary caregiver for following domain activities: activity, social, school, total competence, anxious/depressed, withdrawn/depressed, somatic complaints, internalizing, rule-breaking behavior, aggressive behavior, externalizing, social problems, thought problems, attention problems.Total score for subjects:>5 -<12 years ranged: 0-240, calculated by adding individual score of each domain.Higher scores greater problems in behavior.Analysis performed via PK/PD modelling only if graphical relationship between perampanel exposure;change from baseline in CBCL score(aged >5 -<12 years) could discerned.All subjects received perampanel with seizure frequency,cognition,or AE data with documented dosing history. "number of subjects analyzed": subjects evaluable for this OM; 99999 signifies no discernible graphical relationship between plasma level of perampanel; change from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 23

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	115			
Units: score on a scale				
arithmetic mean (standard deviation)	99999 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Model Predicted Change From Baseline in Total Time to Complete LGPT Score for Dominant Hand in Core Phase of This Study for All Subjects Aged 4 to <12 Years: Assessment Based on Relationship With Plasma Levels of Perampanel

End point title	Model Predicted Change From Baseline in Total Time to Complete LGPT Score for Dominant Hand in Core Phase of This Study for All Subjects Aged 4 to <12 Years: Assessment Based on Relationship With Plasma Levels of Perampanel
-----------------	---

End point description:

Lafayette Grooved Pegboard Test (LGPT) measures visuomotor skills. It is manipulative dexterity test consist of metal matrix of 25 holes; randomly positioned slots.Subjects require to insert 10 grooved pegs into holes.Task needs to complete once for each hand; firstly, dominant hand and by non-dominant hand.Task is timed; scores are time taken for subject to complete all 10 pegs for each hand. If cannot be completed within 300 secs, 300 secs recorded for time.Longer time worsening of visuomotor skills.Analysis was planned to be performed via PK/PD modelling only if graphical relationship between perampanel exposure;change from baseline in Total Time to Complete LGPT Score for Non-dominant Hand could be discerned.All subjects who received perampanel who have seizure frequency,cognition,or AE data documented dosing history."number of subjects analyzed": subjects evaluable for this OM; 99999: no discernible graphical relationship between plasma level of perampanel; change from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 23

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	117			
Units: seconds				
arithmetic mean (standard deviation)	99999 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Model Predicted Change From Baseline in Total Time to Complete LGPT Score for Non-dominant Hand in Core Phase of This Study for All Subjects Aged 4 to <12 Years: Assessment Based on Relationship With Plasma Levels of Perampanel

End point title	Model Predicted Change From Baseline in Total Time to Complete LGPT Score for Non-dominant Hand in Core Phase of This Study for All Subjects Aged 4 to <12 Years: Assessment Based on Relationship With Plasma Levels of Perampanel
-----------------	---

End point description:

Lafayette Grooved Pegboard Test (LGPT) measures visuomotor skills. It is manipulative dexterity test consist of metal matrix of 25 holes; randomly positioned slots. Subjects require to insert 10 grooved pegs into holes. Task needs to complete once for each hand; firstly, dominant hand and by non-dominant hand. Task is timed; scores are time taken for subject to complete all 10 pegs for each hand. If cannot be completed within 300 secs, 300 secs recorded for time. Longer time worsening of visuomotor skills. Analysis was planned to be performed via PK/PD modelling only if graphical relationship between perampanel exposure; change from baseline in Total Time to Complete LGPT Score for Non-dominant Hand could be discerned. All subjects who received perampanel who have seizure frequency, cognition, or AE data documented dosing history. "number of subjects analyzed": subjects evaluable for this OM; 99999: no discernible graphical relationship between plasma level of perampanel; change from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 23

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	113			
Units: seconds				
arithmetic mean (standard deviation)	99999 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Most Frequent Treatment Emergent Adverse Events (AEs) for Total Group of Subjects That Were Considered Related to Perampanel- Core Phase of This Study

End point title	Percentage of Subjects With Most Frequent Treatment Emergent Adverse Events (AEs) for Total Group of Subjects That Were Considered Related to Perampanel- Core Phase of This Study
-----------------	--

End point description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 23 weeks

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	180			
Units: percentage of subjects				
number (not applicable)				
Irritability	12.8			
Nasopharyngitis	14.7			
Influenza	6.4			
Pyrexia	9.0			
Somnolence	13.5			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Aldenkamp-Baker Neuropsychological Assessment Schedule (ABNAS) Score at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Aldenkamp-Baker Neuropsychological Assessment Schedule (ABNAS) Score at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
-----------------	---

End point description:

The ABNAS assessment measured 5 aspects of cognitive function such as fatigue, memory, concentration, motor speed, and reading. The assessment was a measure of subject-perceived cognitive effects of AEDs. This instrument was aimed at assessing subject perceived drug-related cognitive impairment. Total score ranged from 0-72. Higher scores indicate a worsening of these cognitive functions. SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 23, Week 52

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149	31		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n =140,30)	17.7 (± 18.96)	28.6 (± 21.01)		
Change from Baseline at Week 23 (n=107,19)	-1.2 (± 12.77)	3.3 (± 12.42)		
Change from Baseline at Week 52 (n=95,17)	-3.9 (± 16.91)	-0.2 (± 14.67)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Total Child Behavior Check List (CBCL) Score (Age Group 1.5 to 5 Years) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Total Child Behavior Check List (CBCL) Score (Age Group 1.5 to 5 Years) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
-----------------	--

End point description:

The CBCL for subjects (age group 1.5 to 5 years) is a questionnaire to assess behavioral and emotional problems in children as reported by the primary caregiver for the following domains activities: emotionally reactive, anxious/depressed, withdrawn, somatic complaints, internalizing, attention problems, aggressive behavior, externalizing, sleep problems. CBCL total score for subjects (age group 1.5 to 5 years) ranged from 0 to 200, was calculated by adding individual score of each domain. Higher scores indicate greater problems in child behavior. SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment. Here "number of subjects analyzed" signifies subjects who were evaluable for this OM and '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 23, Week 52

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	24	2		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=24,2)	35.0 (± 28.30)	54.0 (± 21.21)		
Change from Baseline at Week 23 (n=15,1)	-0.3 (± 14.71)	-13.0 (± 99999)		

Change from Baseline at Week 52 (n=16,1)	-5.7 (± 14.36)	-11.0 (± 99999)		
---	----------------	-----------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Total Child Behavior Check List (CBCL) Score (Age Group 6 to 18 Years) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Total Child Behavior Check List (CBCL) Score (Age Group 6 to 18 Years) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
-----------------	---

End point description:

CBCL for subjects (age 6 to 18 years) questionnaire to assess behavioral and emotional problems in children as reported by primary caregiver for the following domains activities: activity, social, school, total competence, anxious/depressed, withdrawn/depressed, somatic complaints, internalizing, rule-breaking behavior, aggressive behavior, externalizing, social problems, thought problems, attention problems. Total score for subjects (age group 6 to 18 years) ranged from 0 to 240, calculated by adding individual score of each domain. Higher scores indicate greater problems in child behavior. SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment. Here "number of subjects analyzed" signifies subjects who were evaluable for this OM.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 23, Week 52

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	123	28		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=123,28)	33.3 (± 22.66)	44.6 (± 26.16)		
Change from Baseline at Week 23 (n=96,18)	-0.6 (± 12.26)	-2.2 (± 22.84)		
Change from Baseline at Week 52 (n=86,16)	-1.7 (± 14.51)	-0.7 (± 16.36)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Time to Complete Lafayette Grooved Pegboard Test (LGPT) Scores for 8 Years and Under at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Time to Complete Lafayette Grooved Pegboard Test (LGPT) Scores for 8 Years and Under at Week 23
-----------------	---

End point description:

LGPT test measured visuomotor skills. This test was a manipulative dexterity test that consisted of a metal matrix of 25 holes with randomly positioned slots. The subject was required to insert 10 grooved pegs into the holes. The task was completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. The task was timed and the scores were the time taken for the subject to complete all 10 pegs for each hand. If the test cannot be completed within 300 seconds, 300 seconds were recorded for the time. An increase in score (longer time) indicated worsening of visuomotor skills. The time to complete test is presented as mean seconds plus/minus (+/-) SD. SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment. Here "number of subject analyzed" signifies subject who were evaluable for this OM and CFB indicates change from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 23, Week 52

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	10		
Units: seconds				
arithmetic mean (standard deviation)				
Dominant Hand: Baseline (n=51,10)	196.4 (± 113.12)	155.0 (± 108.10)		
Dominant Hand: CFB :Week 23 (n=36,3)	12.8 (± 49.37)	-4.3 (± 3.79)		
Dominant Hand: CFB: Week 52 (n=28,5)	3.9 (± 50.50)	13.4 (± 33.72)		
Non Dominant Hand: Baseline (n=50,9)	224.3 (± 108.19)	169.6 (± 106.49)		
Non Dominant Hand: CFB Week 23 (n=36,3)	3.3 (± 39.59)	-4.3 (± 14.98)		
Non Dominant Hand: CFB Week 52 (n=29,5)	2.6 (± 46.88)	3.4 (± 29.35)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Time to Complete Lafayette Grooved Pegboard Test (LGPT) Scores Over 8 Years at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Time to Complete Lafayette Grooved Pegboard Test (LGPT) Scores Over 8 Years at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
-----------------	--

End point description:

The LGPT test measured visuomotor skills. This test was a manipulative dexterity test that consisted of a metal matrix of 25 holes with randomly positioned slots. The subject was required to insert 25 grooved pegs into the holes. The task was completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. The task was timed and the scores were the time taken for the subject to complete all 25 pegs for each hand. If the test cannot be completed within 300 seconds, 300 seconds were recorded for the time. An increase in score (longer time) indicated worsening of

visuomotor skills. The time to complete test is presented as mean seconds +/- SD. SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment. Here "number of subjects analyzed" signifies subjects who were evaluable for this OM and CFB indicates change from baseline.

End point type	Secondary
End point timeframe:	
Baseline, Week 23, Week 52	

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	11		
Units: seconds				
arithmetic mean (standard deviation)				
Dominant Hand: Baseline (n=63,11)	189.8 (± 103.58)	150.7 (± 99.68)		
Dominant Hand: CFB at Week 23 (n=50,9)	0.1 (± 21.77)	-11.8 (± 35.05)		
Dominant Hand: CFB at Week 52 (n=44,7)	3.0 (± 21.24)	-15.4 (± 30.43)		
Non Dominant Hand: Baseline (n=61,10)	197.4 (± 100.01)	159.9 (± 84.66)		
Non Dominant Hand: CFB at Week 23 (n=49,8)	7.8 (± 36.03)	-7.0 (± 21.98)		
Non Dominant Hand: CFB at Week 52 (n=42,6)	2.7 (± 23.75)	-28.7 (± 36.15)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Height (a Growth and Development Parameter) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Height (a Growth and Development Parameter) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
-----------------	--

End point description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

End point type	Secondary
End point timeframe:	
Baseline, Week 23, Week 52	

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149	31		
Units: centimeter (cm)				
arithmetic mean (standard deviation)				
Baseline (n=149,29)	126.65 (± 14.293)	131.08 (± 13.311)		
Change from Baseline Week 23 (n=114,18)	2.57 (± 1.926)	1.84 (± 1.111)		
Change from Baseline Week 52 (n=104,17)	5.97 (± 2.580)	5.82 (± 2.544)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Weight (a Growth and Development Parameter) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Weight (a Growth and Development Parameter) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
-----------------	--

End point description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 23, Week 52

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149	31		
Units: kilogram (kg)				
arithmetic mean (standard deviation)				
Baseline (n=149,31)	28.09 (± 10.649)	30.43 (± 11.299)		
Change from Baseline Week 23 (n=117,21)	1.86 (± 2.570)	1.70 (± 3.149)		
Change from Baseline Week 52 (n=104,18)	3.75 (± 4.421)	3.74 (± 4.204)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Thyrotropin Value (a Growth and Development Parameter) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Thyrotropin Value (a Growth and Development Parameter) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
End point description: Thyrotropin level was measured in milli-international units per liter (mIU/L). SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.	
End point type	Secondary
End point timeframe: Baseline, Week 23, Week 52	

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149	31		
Units: mIU/L				
arithmetic mean (standard deviation)				
Baseline (n=146,30)	2.682 (± 1.5897)	3.080 (± 2.2919)		
Change from Baseline Week 23 (n=104,17)	0.141 (± 1.0523)	-0.519 (± 1.4828)		
Change from Baseline Week 52 (n=97,17)	0.112 (± 1.2559)	-0.632 (± 1.5632)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Thyroxine, Free and Triiodothyronine, Free Values (Growth and Development Parameters) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Thyroxine, Free and Triiodothyronine, Free Values (Growth and Development Parameters) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
End point description: SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.	
End point type	Secondary
End point timeframe: Baseline, Week 23, Week 52	

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149	31		
Units: picomoles per liter (pmol/L)				
arithmetic mean (standard deviation)				
Thyroxine,free:Baseline (n=146,30)	15.29 (± 3.993)	15.37 (± 2.160)		
Thyroxine,free:Change Week 23 (n=103,17)	-0.07 (± 4.107)	-0.38 (± 2.088)		
Thyroxine,free:Change Week 52 (n=96,17)	0.10 (± 3.868)	0.08 (± 2.968)		
Triiodothyronine,free:Baseline (n=146,30)	5.96 (± 1.061)	6.10 (± 0.812)		
Triiodothyronine,free: Change Week 23 (n=105,18)	0.06 (± 0.915)	-0.16 (± 0.699)		
Triiodothyronine,free:Change Week 52 (n= 96,17)	0.04 (± 0.987)	-0.04 (± 1.107)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Values (a Growth and Development Parameter) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study

End point title	Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Values (a Growth and Development Parameter) at Week 23 (Core Phase) and at Week 52 (Extension Phase A) of This Study
End point description:	
SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.	
End point type	Secondary
End point timeframe:	
Baseline, Week 23, Week 52	

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149	31		
Units: nanomoles per liter (nmol/L)				
arithmetic mean (standard deviation)				
Baseline (n=144,31)	24.2 (± 14.83)	25.9 (± 13.91)		
Change from Baseline Week 23 (n=107,18)	1.6 (± 8.96)	0.6 (± 7.25)		
Change from Baseline Week 52 (n=96,16)	6.5 (± 9.01)	5.1 (± 8.02)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Change From Baseline in Markedly Abnormal Encephalogram (EEG) Parameter Values During Awake and Sleep State for Total Group of Subject: Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects With Change From Baseline in Markedly Abnormal Encephalogram (EEG) Parameter Values During Awake and Sleep State for Total Group of Subject: Core Phase and Extension Phase A of This Study
-----------------	--

End point description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 52 weeks

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	180			
Units: percentage of subjects	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Encephalogram (EEG) Abnormalities During Awake and Sleep State for Total Group of Subjects: Core Phase and Extension Phase A of This Study

End point title	Number of Encephalogram (EEG) Abnormalities During Awake and Sleep State for Total Group of Subjects: Core Phase and Extension Phase A of This Study
-----------------	--

End point description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 52 weeks

End point values	Perampanel 0.5 mg/mL: All Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	180			
Units: EEG abnormality	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Any Treatment-emergent Reports of Suicidal Ideation and Behavior Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)- Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects With Any Treatment-emergent Reports of Suicidal Ideation and Behavior Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)- Core Phase and Extension Phase A of This Study
-----------------	---

End point description:

C-SSRS: interview-based instrument to systematically assess suicidal ideation (SI); suicidal behavior, whether: completed suicide, suicide attempt (response of "yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior ("yes" on "preparatory acts or behavior", "aborted attempt" or "interrupted attempt"), suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active SI with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any self-injurious behavior with no suicidal intent ("yes" on "has subject engaged in non-suicidal self-injurious behavior"). Percentage of subjects with ≥ 1 positive behavior/ideations, suicidality were reported. C-SSRS performed: ≥ 6 years at time of consent. SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment. "number of subjects analyzed" signifies subjects who were evaluable for this OM.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 weeks

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	27		
Units: percentage of subjects				
number (not applicable)				
Subjects with ≥ 1 Positive Behavior	0.8	0		
Subjects with \geq Positive Ideations	1.6	7.4		
Suicidality	1.6	7.4		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Shift From Baseline in Suicidal Ideation and Behaviors Assessed Using C-SSRS Scores to Extension Phase A (Week 52) of This Study

End point title	Percentage of Subjects With Shift From Baseline in Suicidal Ideation and Behaviors Assessed Using C-SSRS Scores to Extension Phase A (Week 52) of This Study
-----------------	--

End point description:

C-SSRS: interview-based instrument to systematically assess SI and suicidal behavior, to assess whether subject experienced any of the following: completed suicide, suicide attempt (response of "yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior ("yes" on "preparatory acts or behavior", "aborted attempt" or "interrupted attempt"), suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active SI with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any self-injurious behavior with no suicidal intent ("yes" on "has subject engaged in non-suicidal self-injurious behavior"). "w/" refers to "with", "W" refers to "Week" and "&" refers to "and". SAS included all subject who received at least 1 dose of study drug and had at least 1 postdose safety assessment. Here "number of subject analyzed" signifies subject who were evaluable for this measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 weeks

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	27		
Units: percentage of subjects				
number (not applicable)				
No Ideation(Baseline) to No Ideation(Week 52)	96.6	88.9		
Wish to be Dead(Baseline) to No ideation(Week 52)	0.9	3.7		
Active w/ Method(Baseline) to No Ideation(Week 52)	0.9	0		
No Ideation(Baseline)to Active Nonspecific(Week52)	0	3.7		
No Ideation(Baseline) to Active w/ Method(Week 52	0.9	3.7		
No Ideation(Baseline)to Active w/ Intent&Plan(W52)	0.9	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Median Percent Change in Seizure Frequency Per 28 Days During the Treatment Phase Relative to the Pretreatment Phase (Baseline)- Core Phase and Extension Phase A of This Study

End point title	Median Percent Change in Seizure Frequency Per 28 Days
-----------------	--

End point description:

Seizure frequency was based on number of seizures per 28 days, calculated as number of seizures over entire time interval divided by number of days in interval and multiplied by 28. Total POS: sum of all POS including simple partial seizures without motor signs, simple partial seizures with motor signs, complex partial seizures, and complex partial seizures with secondary generalization (SG). Data for this measure has been reported for 13 week time periods as per age groups. Full Analysis Set (FAS) included subjects who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 1-13, Weeks 14-26, Weeks 27-39, Weeks 40-52

End point values	Perampanel 0.5 mg/mL: 4 to <7 Years	Perampanel 0.5 mg/mL: 7 to <12 Years		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	134		
Units: percent change				
median (full range (min-max))				
POS Seizures:Weeks 1-13 (n=40,108)	-47.99 (-100.0 to 79.1)	-40.97 (-100.0 to 549.0)		
POS Seizures:Weeks 14-26 (n=38,91)	-38.93 (-100.0 to 175.0)	-50.77 (-100.0 to 360.5)		
POS Seizures:Weeks 27-39 (n=32,82)	-52.53 (-100.0 to 344.2)	-67.30 (-100.0 to 387.9)		
POS Seizures:Weeks 40-52 (n=31,77)	-58.92 (-100.0 to 482.7)	-70.33 (-100.0 to 436.3)		
PGTC Seizures:Weeks 1-13 (n=3,19)	-100.00 (- 100.0 to 2115.9)	-70.33 (-100.0 to 6783.5)		
PGTC Seizures:Weeks 14-26 (n=3,15)	-100.00 (- 100.0 to -7.7)	-70.70 (-100.0 to 879.1)		
PGTC Seizures:Weeks 27-39 (n=2,13)	-80.77 (-100.0 to -61.5)	-65.43 (-100.0 to 315.4)		
PGTC Seizures:Weeks 40-52 (n=2,11)	-100.00 (- 100.0 to - 100.0)	-96.54 (-100.0 to 658.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Based on 25% Responder Rate- Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects Based on 25% Responder Rate- Core Phase and Extension Phase A of This Study
-----------------	--

End point description:

A 25% responder was a subject who experienced a 25% or greater reduction in seizure frequency per 28 days from baseline. Total POS: sum of all POS including simple partial seizures without motor signs, simple partial seizures with motor signs, complex partial seizures, and complex partial seizures with SG. Data for this OM has been reported for 13 week time periods as per age groups. FAS included subjects

who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 1-13, Weeks 14-26, Weeks 27-39, Weeks 40-52	

End point values	Perampanel 0.5 mg/mL: 4 to <7 Years	Perampanel 0.5 mg/mL: 7 to <12 Years		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	134		
Units: percentage of subjects				
number (not applicable)				
Total POS Seizures: Weeks 1-13	67.5	61.1		
Total POS Seizures: Weeks 14-26	57.9	71.4		
Total POS Seizures: Weeks 27-39	71.9	78.0		
Total POS Seizures: Weeks 40-52	71.0	81.8		
PGTC Seizures: Weeks 1-13	66.7	73.7		
PGTC Seizures: Weeks 14-26	66.7	73.3		
PGTC Seizures: Weeks 27-39	100.0	69.2		
PGTC Seizures: Weeks 40-52	100.0	63.6		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Based on 50% Responder Rate- Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects Based on 50% Responder Rate- Core Phase and Extension Phase A of This Study
End point description:	
A 50% responder was a subject who experienced a 50% or greater reduction in seizure frequency per 28 days from baseline. Total POS: sum of all POS including simple partial seizures without motor signs, simple partial seizures with motor signs, complex partial seizures, and complex partial seizures with SG. Data for this OM has been reported for 13 week time periods as per age groups. FAS included subjects who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 1-13, Weeks 14-26, Weeks 27-39, Weeks 40-52	

End point values	Perampanel 0.5 mg/mL: 4 to <7 Years	Perampanel 0.5 mg/mL: 7 to <12 Years		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	134		
Units: percentage of subjects				
number (not applicable)				

Total POS Seizures: Weeks 1-13	47.5	45.4		
Total POS Seizures: Weeks 14-26	44.7	50.5		
Total POS Seizures: Weeks 27-39	53.1	65.9		
Total POS Seizures: Weeks 40-52	61.3	62.3		
PGTC Seizures: Weeks 1-13	66.7	57.9		
PGTC Seizures: Weeks 14-26	66.7	60.0		
PGTC Seizures: Weeks 27-39	100.0	61.5		
PGTC Seizures: Weeks 40-52	100.0	54.5		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Based on 75% Responder Rate- Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects Based on 75% Responder Rate- Core Phase and Extension Phase A of This Study
-----------------	--

End point description:

A 75% responder was a subject who experienced a 75% or greater reduction in seizure frequency per 28 days from baseline. Total POS: sum of all POS including simple partial seizures without motor signs, simple partial seizures with motor signs, complex partial seizures, and complex partial seizures with SG. Data for this OM has been reported for 13 week time periods as per age groups. FAS included subjects who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 1-13, Weeks 14-26, Weeks 27-39, Weeks 40-52

End point values	Perampanel 0.5 mg/mL: 4 to <7 Years	Perampanel 0.5 mg/mL: 7 to <12 Years		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	134		
Units: percentage of subjects				
number (not applicable)				
Total POS Seizures: Weeks 1-13	17.5	25.0		
Total POS Seizures: Weeks 14-26	18.4	34.1		
Total POS Seizures: Weeks 27-39	31.3	46.3		
Total POS Seizures: Weeks 40-52	38.7	41.6		
PGTC Seizures: Weeks 1-13	66.7	47.4		
PGTC Seizures: Weeks 14-26	66.7	46.7		
PGTC Seizures: Weeks 27-39	50.0	46.2		
PGTC Seizures: Weeks 40-52	100.0	54.5		

Statistical analyses

Secondary: Percentage of Subjects Who Were Seizure-free- Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects Who Were Seizure-free- Core Phase and Extension Phase A of This Study
-----------------	--

End point description:

Subjects were considered seizure free if subjects completed a 13-week time period and were seizure-free for that entire time period. Total POS: sum of all POS including simple partial seizures without motor signs, simple partial seizures with motor signs, complex partial seizures, and complex partial seizures with SG. Data for this OM has been reported for 13 week time periods as per age groups. FAS included subjects who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 1-13, Weeks 14-26, Weeks 27-39, Weeks 40-52

End point values	Perampanel 0.5 mg/mL: 4 to <7 Years	Perampanel 0.5 mg/mL: 7 to <12 Years		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	46	134		
Units: percentage of subjects				
number (not applicable)				
Total POS Seizures: Weeks 1-13	7.9	9.9		
Total POS Seizures: Weeks 14-26	9.4	15.9		
Total POS Seizures: Weeks 27-39	12.9	24.7		
Total POS Seizures: Weeks 40-52	15.0	20.8		
PGTC Seizures: Weeks 1-13	66.7	40.0		
PGTC Seizures: Weeks 14-26	50.0	46.2		
PGTC Seizures: Weeks 27-39	50.0	45.5		
PGTC Seizures: Weeks 40-52	100.0	57.1		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Clinical Global Impression of Change Scores (CGIC)- Core Phase and Extension Phase A of This Study

End point title	Percentage of Subjects With Clinical Global Impression of Change Scores (CGIC)- Core Phase and Extension Phase A of This Study
-----------------	--

End point description:

Assessment of disease severity utilized the CGIC scale at end of treatment to evaluate subject's change in disease status from baseline. The CGIC is a 7-point scale that measures a physician's global impression of a subject's clinical condition. Scale ranged from 1 to 7 with lower score indicated improvement (1=very much improved, 2=much improved, 3=minimally improved), higher score indicated worsening (5=minimally worse, 6= much worse, 7=very much worse), and a score of 4 indicated no change. FAS included subjects who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 23, Week 52

End point values	Perampanel 0.5 mg/mL: POS	Perampanel 0.5 mg/mL: PGTC Seizures		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149	31		
Units: percentage of subjects				
number (not applicable)				
Week 23: Very much improved	11.5	8.7		
Week 23: Much improved	31.1	26.1		
Week 23: Minimally improved	38.5	26.1		
Week 23: No change	14.8	26.1		
Week 23: Minimally worse	3.3	13.0		
Week 23: Much worse	0.8	0		
Week 52: Very much improved	14.4	5.9		
Week 52: Much improved	39.4	41.2		
Week 52: Minimally improved	35.6	29.4		
Week 52: No change	7.7	17.6		
Week 52: Minimally worse	1.9	5.9		
Week 52: Much worse	1.0	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From baseline up to approximately 5 years

Adverse event reporting additional description:

SAS included all subjects who received at least 1 dose of study drug and had at least 1 postdose safety assessment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	Perampanel 0.5 mg/mL: POS
-----------------------	---------------------------

Reporting group description:

Core Phase: Subjects with POS received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel once daily at optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed Core Phase, entered Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Reporting group title	Extension B: Perampanel 0.5 mg/mL: PGTC Seizures
-----------------------	--

Reporting group description:

Subjects who completed Core Phase and Extension Phase A entered Extension Phase B, and continued with their optimal perampanel dose from Core Phase until a subject reached 12 years of age, switched to the commercial perampanel product, or discontinued for safety or administrative reasons.

Reporting group title	Extension B: Perampanel 0.5 mg/mL: POS
-----------------------	--

Reporting group description:

Subjects who completed Core Phase and Extension Phase A entered Extension Phase B, and continued with their optimal perampanel dose from Core Phase until a subject reached 12 years of age, switched to the commercial perampanel product, or discontinued for safety or administrative reasons.

Reporting group title	Perampanel 0.5 mg/mL: PGTC Seizures
-----------------------	-------------------------------------

Reporting group description:

Core Phase: Subjects with PGTC seizures received perampanel 0.5 mg/mL oral suspension titrated beyond 8 mg/day up to 12 mg/day, if 8 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are not taking any other EIAED), or titrated beyond 12 mg/day up to 16 mg/day, if 12 mg/day was tolerable and were deemed likely to be benefitted by higher dose (for subjects who are taking any EIAED). Dose titration- up to 11 weeks to identify each subject's optimum dose. Subjects then continued to take perampanel oral suspension once daily at the optimal dose level as a maintenance dose for up to 12 weeks. Extension Phase A: Subjects who completed the Core Phase, entered the Extension Phase A, and continued with their optimal perampanel dose from Core Phase for up to 29 weeks. Total duration of treatment for Core Phase and Extension Phase A was up to 52 weeks.

Serious adverse events	Perampanel 0.5 mg/mL: POS	Extension B: Perampanel 0.5 mg/mL: PGTC Seizures	Extension B: Perampanel 0.5 mg/mL: POS
Total subjects affected by serious adverse events			
subjects affected / exposed	29 / 149 (19.46%)	0 / 1 (0.00%)	8 / 41 (19.51%)
number of deaths (all causes)	1	0	0
number of deaths resulting from	1	0	0

adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign neoplasm of testis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemangioma			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Subgaleal haematoma			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dysarthria			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ataxia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Focal dyscognitive seizures			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rasmussen encephalitis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal epilepsy			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure cluster			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Gait disturbance			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Dental caries			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Atelectasis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract inflammation			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Aggression			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disruptive mood dysregulation disorder			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, visual			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Epiphysiolysis			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 7	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	5 / 41 (12.20%)
occurrences causally related to treatment / all	0 / 7	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection pseudomonal			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			

subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral myocarditis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device malfunction			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			

Dehydration			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Perampanel 0.5 mg/mL: PGTC Seizures		
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 31 (22.58%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign neoplasm of testis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral haemangioma			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Subgaleal haematoma			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Dysarthria			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ataxia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epilepsy			

subjects affected / exposed	1 / 31 (3.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Focal dyscognitive seizures			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Rasmussen encephalitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Petit mal epilepsy			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Seizure			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Seizure cluster			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Somnolence			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Gait disturbance			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperthermia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Dental caries			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis erosive			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enterocolitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			

Acute respiratory failure				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Asthma				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atelectasis				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract inflammation				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory distress				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia aspiration				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychiatric disorders				
Aggression				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Disruptive mood dysregulation disorder				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Hallucination, visual			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Epiphysiolysis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Encephalitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Influenza			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection pseudomonal			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Rhinovirus infection				
subjects affected / exposed	1 / 31 (3.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Viral infection				
subjects affected / exposed	1 / 31 (3.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Viral myocarditis				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchiolitis				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis acute				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pharyngitis				
subjects affected / exposed	0 / 31 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Product issues				

Device malfunction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 31 (0.00%) 0 / 0 0 / 0		
Metabolism and nutrition disorders Dehydration subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 31 (0.00%) 0 / 0 0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Perampanel 0.5 mg/mL: POS	Extension B: Perampanel 0.5 mg/mL: PGTC Seizures	Extension B: Perampanel 0.5 mg/mL: POS
Total subjects affected by non-serious adverse events subjects affected / exposed	135 / 149 (90.60%)	1 / 1 (100.00%)	34 / 41 (82.93%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Vascular disorders Peripheral coldness subjects affected / exposed occurrences (all) Subgaleal haematoma subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1 0 / 149 (0.00%) 0	0 / 1 (0.00%) 0 0 / 1 (0.00%) 0	0 / 41 (0.00%) 0 1 / 41 (2.44%) 1
General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all) Crying subjects affected / exposed occurrences (all) Fatigue	1 / 149 (0.67%) 1 1 / 149 (0.67%) 1	0 / 1 (0.00%) 0 0 / 1 (0.00%) 0	0 / 41 (0.00%) 0 0 / 41 (0.00%) 0

subjects affected / exposed	9 / 149 (6.04%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	11	0	0
Gait disturbance			
subjects affected / exposed	7 / 149 (4.70%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	7	0	0
Influenza like illness			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Pyrexia			
subjects affected / exposed	25 / 149 (16.78%)	0 / 1 (0.00%)	4 / 41 (9.76%)
occurrences (all)	39	0	4
Medical device pain			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Screaming			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Rubber sensitivity			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Seasonal allergy			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	5	0	0
Asthma			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	2	0	1
Epistaxis			

subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	6	0	0
Lower respiratory tract congestion			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Increased upper airway secretion			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Oropharyngeal pain			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	5	0	1
Nasal congestion			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Productive cough			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	4	0	0
Rhinitis allergic			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract inflammation			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	3 / 41 (7.32%)
occurrences (all)	4	0	3
Respiratory disorder			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Sleep apnoea syndrome			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Upper airway obstruction			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Bronchitis chronic			

subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Increased bronchial secretion subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Pneumonia aspiration subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Psychiatric disorders			
Abnormal behaviour subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Adjustment disorder subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Affect lability subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Agitation subjects affected / exposed occurrences (all)	7 / 149 (4.70%) 11	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Aggression subjects affected / exposed occurrences (all)	15 / 149 (10.07%) 22	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Anger subjects affected / exposed occurrences (all)	3 / 149 (2.01%) 3	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	3 / 149 (2.01%) 5	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Attention deficit/hyperactivity disorder subjects affected / exposed occurrences (all)	4 / 149 (2.68%) 4	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Defiant behaviour			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Bradyphrenia			
subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	6	0	0
Dysphemia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Dysphoria			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Enuresis			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	4	0	0
Euphoric mood			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Hypervigilance			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	5	0	2
Irritability			
subjects affected / exposed	19 / 149 (12.75%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	20	0	1
Learning disability			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Mood altered			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Middle insomnia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Nightmare			

subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Oppositional defiant disorder			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Negativism			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Personality change			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Restlessness			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	2	0	1
Somnambulism			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Suicidal ideation			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Tic			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Distractibility			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Initial insomnia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Intentional self-injury			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Investigations			

Body temperature increased subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 2	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Urine output decreased subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 2	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Weight decreased subjects affected / exposed occurrences (all)	3 / 149 (2.01%) 3	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	6 / 149 (4.03%) 6	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Blood pressure systolic increased subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Crystal urine present subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Blood uric acid increased subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Eosinophil count increased subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Tri-iodothyronine free increased subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
White blood cells urine positive			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Ammonia increased			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Blast cell count increased			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	0	0	3
Neutrophil count decreased			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Animal bite			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Arthropod sting			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	6 / 149 (4.03%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	6	0	1
Eye contusion			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Eye injury			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Fall			

subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Head injury			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	2
Foot fracture			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Forearm fracture			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Laceration			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Joint injury			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Ligament sprain			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	2	0	1
Limb injury			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Mallet finger			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Nail avulsion			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Scar			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Seroma			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			

subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	5	0	1
Wound			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	1
Thermal burn			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Wrist fracture			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Clavicle fracture			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Joint dislocation			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Heat stroke			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Stoma site hypergranulation			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Traumatic haematoma			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Arthropod bite			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Femur fracture			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Incision site erosion			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Lip injury			

subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Nervous system disorders			
Amnesia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Ataxia			
subjects affected / exposed	6 / 149 (4.03%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	10	0	0
Atonic seizures			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	8	0	0
Cerebral haematoma			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Coordination abnormal			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Clumsiness			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Cognitive disorder			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Dizziness			
subjects affected / exposed	19 / 149 (12.75%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	24	0	0
Disturbance in attention			
subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	5	0	0
Droping			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	4	0	0

Dysarthria			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Dyslexia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Focal dyscognitive seizures			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Dysstasia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	10 / 149 (6.71%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	18	0	1
Hypotonia			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Lethargy			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Memory impairment			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Motor dysfunction			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Nystagmus			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Persistent postural-perceptual dizziness			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Petit mal epilepsy			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Postictal state			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Psychomotor hyperactivity			
subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	6	0	0
Psychomotor skills impaired			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Sedation			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	6 / 149 (4.03%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	9	0	0
Somnolence			
subjects affected / exposed	43 / 149 (28.86%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	49	0	1
Status epilepticus			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Epilepsy			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Hippocampal sclerosis			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Poor quality sleep			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Seizure cluster			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	2
Simple partial seizures			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Tremor			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Myoclonus			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Fine motor skill dysfunction			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Increased tendency to bruise			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Thrombocytopenia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Iron deficiency anaemia			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Macrocytosis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Ear and labyrinth disorders			
Ear pain			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Tympanic membrane perforation			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Vertigo			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Eye disorders			
Conjunctivitis allergic			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	4 / 41 (9.76%)
occurrences (all)	2	0	5
Corneal disorder			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Diplopia			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	4	0	0
Mydriasis			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Conjunctival hyperaemia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Keratitis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	1	0	2
Strabismus			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Eye discharge			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1

Eyelid oedema			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Lagophthalmos			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	8	0	0
Abdominal pain upper			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Constipation			
subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	5	0	3
Anal incontinence			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	9 / 149 (6.04%)	0 / 1 (0.00%)	3 / 41 (7.32%)
occurrences (all)	13	0	6
Dry mouth			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Dysphagia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	2	0	1
Enteritis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Erosive oesophagitis			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Haematemesis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	4	0	1
Odynophagia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Salivary hypersecretion			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	6	0	0
Stomatitis			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Toothache			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Vomiting			
subjects affected / exposed	20 / 149 (13.42%)	0 / 1 (0.00%)	5 / 41 (12.20%)
occurrences (all)	23	0	13
Dental caries			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	1	0	2
Functional gastrointestinal disorder			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Ranula			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Enterocolitis			

subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Gastritis			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Gastrointestinal motility disorder			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Gingival hypertrophy			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Haemorrhoids			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Tooth discolouration			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Hepatobiliary disorders			
Drug-induced liver injury			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Alopecia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Dermatitis contact			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	4	0	1
Dermatitis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	3 / 41 (7.32%)
occurrences (all)	1	0	3
Drug eruption			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Dermatitis diaper			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Eczema			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	2	0	2
Mechanical urticaria			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	1
Rash			
subjects affected / exposed	6 / 149 (4.03%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	13	0	2
Miliaria			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Rash erythematous			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Rash morbilliform			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	4	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Angioedema			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Dermatitis atopic			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	1
Rash generalised			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Rash maculo-papular			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Skin erosion			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Blister			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Decubitus ulcer			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Yellow skin			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Nail dystrophy			
subjects affected / exposed	0 / 149 (0.00%)	1 / 1 (100.00%)	0 / 41 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Urinary incontinence			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	4	0	0
Polyuria			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0

Hypertonic bladder subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Proteinuria subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Vesicoureteric reflux subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Endocrine disorders			
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Precocious puberty subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	1 / 41 (2.44%) 1
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Kyphosis subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	1 / 149 (0.67%) 1	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Muscle rigidity subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 149 (0.00%) 0	0 / 1 (0.00%) 0	0 / 41 (0.00%) 0
Periosteal haematoma			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Arthritis			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	4	0	0
Beta haemolytic streptococcal infection			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	10 / 149 (6.71%)	0 / 1 (0.00%)	4 / 41 (9.76%)
occurrences (all)	11	0	6
Conjunctivitis			
subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	4 / 41 (9.76%)
occurrences (all)	5	0	5
Ear infection			
subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Enterocolitis viral			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Fungal skin infection			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Fungal infection			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	11 / 149 (7.38%)	1 / 1 (100.00%)	1 / 41 (2.44%)
occurrences (all)	14	1	1
Hordeolum			

subjects affected / exposed	3 / 149 (2.01%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Influenza			
subjects affected / exposed	20 / 149 (13.42%)	0 / 1 (0.00%)	6 / 41 (14.63%)
occurrences (all)	23	0	6
Lymphangitis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	40 / 149 (26.85%)	0 / 1 (0.00%)	14 / 41 (34.15%)
occurrences (all)	73	0	25
Oral herpes			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Otitis externa			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	1
Otitis media			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	1
Otitis media acute			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	6 / 149 (4.03%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	6	0	2
Paronychia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Pharyngitis streptococcal			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	3	0	0
Pneumonia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	6 / 41 (14.63%)
occurrences (all)	1	0	8
Respiratory tract infection			

subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	4	0	0
Respiratory tract infection viral			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	5	0	0
Streptococcal infection			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	3 / 41 (7.32%)
occurrences (all)	1	0	4
Tonsillitis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	2	0	1
Upper respiratory tract infection			
subjects affected / exposed	15 / 149 (10.07%)	0 / 1 (0.00%)	3 / 41 (7.32%)
occurrences (all)	17	0	6
Urinary tract infection			
subjects affected / exposed	5 / 149 (3.36%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	6	0	0
Viral infection			
subjects affected / exposed	4 / 149 (2.68%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	6	0	1
Viral rash			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Croup infectious			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			

subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Herpes zoster			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Impetigo			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	1
Oral fungal infection			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Perianal streptococcal infection			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Tinea pedis			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Varicella			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	1	0	2
Corona virus infection			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Erythema infectiosum			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Folliculitis			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Lower respiratory tract infection			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	2 / 41 (4.88%)
occurrences (all)	0	0	2
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Pyelonephritis acute			

subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 149 (1.34%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	2	0	0
Increased appetite			
subjects affected / exposed	6 / 149 (4.03%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	6	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Polydipsia			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Dehydration			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Hypoglycaemia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 149 (0.67%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	1
Hypokalaemia			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Vitamin D deficiency			
subjects affected / exposed	0 / 149 (0.00%)	0 / 1 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1

Non-serious adverse events	Perampanel 0.5 mg/mL: PGTC Seizures		
Total subjects affected by non-serious adverse events subjects affected / exposed	25 / 31 (80.65%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Vascular disorders Peripheral coldness subjects affected / exposed occurrences (all) Subgaleal haematoma subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0 0 / 31 (0.00%) 0		
General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all) Crying subjects affected / exposed occurrences (all) Fatigue subjects affected / exposed occurrences (all) Gait disturbance subjects affected / exposed occurrences (all) Influenza like illness subjects affected / exposed occurrences (all) Pain subjects affected / exposed occurrences (all) Pyrexia	1 / 31 (3.23%) 2 0 / 31 (0.00%) 0 2 / 31 (6.45%) 2 0 / 31 (0.00%) 0 1 / 31 (3.23%) 1 0 / 31 (0.00%) 0		

subjects affected / exposed	4 / 31 (12.90%)		
occurrences (all)	6		
Medical device pain			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Screaming			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Immune system disorders			
Rubber sensitivity			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Seasonal allergy			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	7		
Asthma			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	3		
Lower respiratory tract congestion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Increased upper airway secretion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nasal congestion			

subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Productive cough			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Rhinitis allergic			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Respiratory disorder			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Sleep apnoea syndrome			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Upper airway obstruction			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Bronchitis chronic			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Increased bronchial secretion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Pneumonia aspiration			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Abnormal behaviour			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		

Adjustment disorder			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Affect lability			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Agitation			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Aggression			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Anger			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Anxiety			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Attention deficit/hyperactivity disorder			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Defiant behaviour			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Bradyphrenia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Dysphemia			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Dysphoria			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Enuresis			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Euphoric mood			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Hypervigilance			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	3		
Irritability			
subjects affected / exposed	5 / 31 (16.13%)		
occurrences (all)	5		
Learning disability			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Mood altered			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Middle insomnia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nightmare			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Oppositional defiant disorder			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Negativism			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Personality change			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Restlessness			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Somnambulism			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Suicidal ideation			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	2		
Sleep disorder			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Tic			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Distractibility			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Initial insomnia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Intentional self-injury			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Investigations			
Body temperature increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Urine output decreased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Weight increased			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		

Alanine aminotransferase increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Blood pressure systolic increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Crystal urine present			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Blood uric acid increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Eosinophil count increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Tri-iodothyronine free increased			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
White blood cells urine positive			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Ammonia increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Blast cell count increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Animal bite			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Arthropod sting			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Contusion			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Eye contusion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Eye injury			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	3		
Head injury			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Foot fracture			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Forearm fracture			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Laceration			

subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	3		
Joint injury			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Limb injury			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Mallet finger			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nail avulsion			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Scar			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Seroma			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Skin abrasion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Wound			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Thermal burn			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Wrist fracture			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Clavicle fracture			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Joint dislocation			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Heat stroke			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Stoma site hypergranulation			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Traumatic haematoma			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Arthropod bite			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Femur fracture			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Incision site erosion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Lip injury			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Amnesia			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Ataxia			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Atonic seizures			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		

Balance disorder			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	3		
Cerebral haematoma			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Coordination abnormal			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Clumsiness			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Cognitive disorder			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	5 / 31 (16.13%)		
occurrences (all)	8		
Disturbance in attention			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Droling			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Dysarthria			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Dyslexia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Focal dyscognitive seizures			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Dysstasia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		

Headache			
subjects affected / exposed	5 / 31 (16.13%)		
occurrences (all)	7		
Hypotonia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Lethargy			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Memory impairment			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	3		
Motor dysfunction			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Nystagmus			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Persistent postural-perceptual dizziness			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Petit mal epilepsy			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Postictal state			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Psychomotor hyperactivity			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	3		
Psychomotor skills impaired			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Sedation			

subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	3		
Seizure			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	4		
Somnolence			
subjects affected / exposed	5 / 31 (16.13%)		
occurrences (all)	9		
Status epilepticus			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Epilepsy			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Hippocampal sclerosis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Migraine			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Poor quality sleep			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Seizure cluster			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Simple partial seizures			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Myoclonus			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Fine motor skill dysfunction			

subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Increased tendency to bruise			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Thrombocytopenia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Iron deficiency anaemia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Macrocytosis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Tympanic membrane perforation			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Vertigo			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	3		
Eye disorders			
Conjunctivitis allergic			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Corneal disorder			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Diplopia			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	2		
Mydriasis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Vision blurred			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Conjunctival hyperaemia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Keratitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Strabismus			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Eye discharge			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Eyelid oedema			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Lagophthalmos			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Abdominal pain			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		

Abdominal pain upper			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	5		
Anal incontinence			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	5		
Dry mouth			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Dysphagia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Enteritis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Erosive oesophagitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Haematemesis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Odynophagia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		

Salivary hypersecretion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	5 / 31 (16.13%)		
occurrences (all)	6		
Dental caries			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Functional gastrointestinal disorder			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Ranula			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Enterocolitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Gastritis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Gastrointestinal motility disorder			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Gingival hypertrophy			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Haemorrhoids			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		

Tooth discolouration subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Hepatobiliary disorders Drug-induced liver injury subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Skin and subcutaneous tissue disorders Acne subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Alopecia subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Dermatitis contact subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Dermatitis subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Drug eruption subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Dermatitis diaper subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Eczema subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1		
Mechanical urticaria subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Erythema subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0		
Rash			

subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Miliaria			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Rash erythematous			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Rash papular			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Rash morbilliform			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Urticaria			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Skin hyperpigmentation			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Angioedema			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Dermatitis atopic			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Rash generalised			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Skin erosion			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Blister			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Decubitus ulcer			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Yellow skin			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nail dystrophy			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Urinary incontinence			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Polyuria			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Haematuria			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Hypertonic bladder			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Pollakiuria			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Proteinuria			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Vesicoureteric reflux			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Endocrine disorders			
Hypothyroidism			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Precocious puberty			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Kyphosis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Muscle spasms			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Muscle rigidity			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	2		
Pain in extremity			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Periosteal haematoma			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Arthritis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Beta haemolytic streptococcal infection			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Bronchitis			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Ear infection			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Enterocolitis viral			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Fungal skin infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Fungal infection			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Gastroenteritis			
subjects affected / exposed	2 / 31 (6.45%)		
occurrences (all)	2		
Hordeolum			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Lymphangitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	4		
Oral herpes			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Otitis externa			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Otitis media			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Otitis media acute			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Pharyngitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Paronychia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Pharyngitis streptococcal			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Pneumonia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Respiratory tract infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Respiratory tract infection viral			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Sinusitis			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	4		
Streptococcal infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Tonsillitis			

subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	3 / 31 (9.68%)		
occurrences (all)	3		
Urinary tract infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Viral infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Viral rash			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	2		
Croup infectious			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Gastroenteritis viral			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Herpes zoster			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Impetigo			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Oral fungal infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Perianal streptococcal infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Tinea pedis			

subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Varicella			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Corona virus infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Erythema infectiosum			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Folliculitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Lower respiratory tract infection			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Pyelonephritis acute			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	4 / 31 (12.90%)		
occurrences (all)	4		
Increased appetite			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Hyperuricaemia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		

Polydipsia			
subjects affected / exposed	1 / 31 (3.23%)		
occurrences (all)	1		
Dehydration			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Hypoglycaemia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Hyponatraemia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Hypophosphataemia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		
Vitamin D deficiency			
subjects affected / exposed	0 / 31 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 April 2017	Amendment 01: Added that the Titration Period is a fixed duration of 11 weeks and subjects will remain on their optimum dose once it is achieved during this period. Separated the Titration Period dosing schedule into separate presentations for Global sites and Japan sites. Increased the time prior to Visit 2 that subjects must meet the prior seizure criterion from 4 to 12 weeks. Increased the number of approved antiepileptic drug (AEDs) subjects may currently be receiving from 2 to 3. Added exclusion criterion for cannabinoids. Added exclusion of subjects with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Added emphasis that efforts should be made to perform all clinical laboratory and screening tests on the scheduled day, or as close as possible to that day, within 4 week period prior Visit 2. Added emphasis that efforts should be made to perform all clinical laboratory and screening tests on the scheduled day, or as close as possible to that day, within 4 week period prior Visit 2. Added mandatory blood collection for pharmacokinetic (PK) assessment. Revised study visit window to ± 7 days of the scheduled visit. Grammatical, typographical, and formatting changes were also made.
19 October 2017	Amendment 02: Revised the Pretreatment Screening/Baseline Period (outside of Japan) to allow subjects to enrol sooner after a qualifying seizure, while maintaining the 4 weeks ± 3 days required in Japan. Added that the study period durations were "up to" the specified nominal times. Added that analyses for regional submissions may be performed during the course of the study. Revised the sample size to state "at least" 160 subjects "(with up to 40 subjects with PGTC and the balance with POS)". Added that each study visit is based on the actual prior visit (eg, Visit 3 is completed 2 weeks ± 3 days of Visit 2, Visit 4 is completed 3 weeks ± 3 days of Visit 3, etc). Revised study visit window during the Extension Phase back to ± 6 days of the scheduled visit for Visits 10 through 12 (as per the original protocol). Grammatical, typographical, and formatting changes were also made.
19 January 2018	Amendment 03: Clarified, in the text, that the Followup Visit would be conducted at 4 weeks ± 7 days after the last dose of study drug for all subjects, except for subjects entering into Extension A. Clarified, in the text, that the follow-up period of Extension A was only for subjects not entering into Extension B and that Extension B will occur in Japan only. Clarified, in the text, that a follow-up period of Extension B, would include a Follow-up visit at 4 weeks ± 7 days after the Discontinuation Visit, and would occur for subjects who discontinue or who choose not to switch to the commercial product. Clarified, in the text, that subjects in all countries can enroll in Extension A. Clarified that the study visit window during Extension B is ± 6 days of the scheduled visit. Clarified that the initial assessment of Extension B was performed at the final visit of Extension A Maintenance period (ie, Visit 12). Grammatical, typographical, and formatting changes were also made.
13 July 2018	Amendment 04: Clarified, in the text, that the Pretreatment Phase consists of a Screening/Baseline period. Clarified, in the text, the approximate total study duration. Clarified, in the text, that subjects in Japan and in countries where an extended access program (EAP) cannot be implemented can enroll in Extension B. Specified criteria for participation in Extension B for subjects in countries where an EAP cannot be implemented. Clarified the CGI objective (CGIS is the baseline assessment and CGIC is the postbaseline assessment of the CGI). Grammatical, typographical, and formatting changes were also made.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported